Inozyme Pharma (NASDAQ:INZY - Get Free Report)'s stock had its "buy" rating reiterated by analysts at Needham & Company LLC in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $23.00 price target on the stock. Needham & Company LLC's target price suggests a potential upside of 395.69% from the stock's previous close.
INZY has been the subject of a number of other research reports. Wedbush restated an "outperform" rating and set a $15.00 price objective on shares of Inozyme Pharma in a report on Tuesday. Bank of America decreased their price target on shares of Inozyme Pharma from $16.00 to $14.00 and set a "buy" rating for the company in a research note on Tuesday, April 9th. Finally, HC Wainwright reiterated a "buy" rating and issued a $16.00 price objective on shares of Inozyme Pharma in a research note on Wednesday, March 13th.
Get Our Latest Report on Inozyme Pharma
Inozyme Pharma Stock Up 0.9 %
Inozyme Pharma stock traded up $0.04 during midday trading on Wednesday, hitting $4.64. 392,061 shares of the stock were exchanged, compared to its average volume of 605,900. Inozyme Pharma has a 52-week low of $2.69 and a 52-week high of $7.80. The business's 50-day moving average price is $5.66 and its 200-day moving average price is $4.75. The company has a quick ratio of 13.36, a current ratio of 13.36 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $287.03 million, a price-to-earnings ratio of -3.31 and a beta of 1.54.
Inozyme Pharma (NASDAQ:INZY - Get Free Report) last posted its quarterly earnings data on Tuesday, March 12th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.04). On average, research analysts expect that Inozyme Pharma will post -1.46 EPS for the current fiscal year.
Insider Activity at Inozyme Pharma
In other Inozyme Pharma news, CEO Douglas A. Treco sold 7,523 shares of the stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $6.94, for a total transaction of $52,209.62. Following the sale, the chief executive officer now owns 20,665 shares in the company, valued at $143,415.10. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 11.88% of the stock is owned by company insiders.
Institutional Trading of Inozyme Pharma
Several institutional investors and hedge funds have recently bought and sold shares of INZY. Strs Ohio bought a new position in shares of Inozyme Pharma in the third quarter worth $41,000. Values First Advisors Inc. bought a new stake in shares of Inozyme Pharma during the 4th quarter valued at about $59,000. SG Americas Securities LLC purchased a new position in shares of Inozyme Pharma during the third quarter worth about $61,000. Superstring Capital Management LP bought a new position in shares of Inozyme Pharma in the fourth quarter worth approximately $528,000. Finally, Schonfeld Strategic Advisors LLC raised its stake in Inozyme Pharma by 346.8% in the third quarter. Schonfeld Strategic Advisors LLC now owns 311,880 shares of the company's stock valued at $1,310,000 after purchasing an additional 242,080 shares in the last quarter. 88.30% of the stock is currently owned by hedge funds and other institutional investors.
About Inozyme Pharma
(
Get Free Report)
Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.
Further Reading
Before you consider Inozyme Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inozyme Pharma wasn't on the list.
While Inozyme Pharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
